Wigzell Hans Lennart Rudolf 4
4 · Sarepta Therapeutics, Inc. · Filed Dec 16, 2024
Insider Transaction Report
Form 4
Wigzell Hans Lennart Rudolf
Director
Transactions
- Exercise/Conversion
Stock Options (right to buy)
2024-12-12−10,500→ 0 totalExercise: $13.71From: 2017-02-28Exp: 2026-02-28→ Common Stock (10,500 underlying) - Exercise/Conversion
Common Stock
2024-12-12$13.71/sh+10,500$143,955→ 33,340 total - Sale
Common Stock
2024-12-12$124.84/sh−10,500$1,310,820→ 22,840 total
Footnotes (1)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.92 to $124.80, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.